November 20, 2018, Vancouver, BC – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce the appointment of Blair Lowther and Nick Standish as Directors of the Company.

Lui Franciosi commented: “We are very pleased to welcome Mr. Blair Lowther and Mr. Nick Standish to Veritas’ Board of Directors. Both new directors add valuable knowledge in this growing industry. Their experience in raising funds and running cannabis-related operations will be significant assets to us as we continue to advance our corporate objectives.”

Mr. Lowther brings a wealth of legal experience as a commercial lawyer with Miller Thomson LLP in Vancouver. Currently, he is an executive with BlocPal International Inc., a Director for Sport BC, and is a Guest Lecturer & Contributing Author for the Sauder School of Business at UBC. Mr. Lowther commented: “I am excited to be part of Veritas’ mission and vision addressing scientific evidence for validation of claims made in the medical cannabis industry.”

Mr. Standish brings a great deal of business experience as CEO of Stamatis Ventures Ltd. Through Stamatis, Mr. Standish has co-founded: Integro Management Solutions, a cannabis related management and consulting company; and, an agricultural technology joint venture between Stamatis, Enviro Systems Inc. and Miracle Valley Medicinal Alternatives.

The Company would also like to announce the resignation of Dr. Donald Carlow and Mr. Yari Nieken as Directors of the Company. Both Dr. Carlow and Mr. Nieken have agreed to remain with the Company as members of the Company’s Advisory Board. The Company would like to thank both Donald and Yari for their services and wish them both success in their present and future endeavors.

About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.

Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website:

On behalf of the Board of Directors

“Dr. Lui Franciosi”
Dr. Lui Franciosi
President and Chief Executive Officer

Further information about the Company is available on our website at or under our profile on SEDAR at and on the CSE website at

Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: [email protected]

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!